Design Therapeutics, Inc. Proceeds from Sale of Productive Assets
Design Therapeutics, Inc. (DSGN) reported Proceeds from Sale of Productive Assets of $39.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-19.
Discontinued › Cash Flow
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2024-03-19
- Design Therapeutics, Inc. proceeds from sale of productive assets for the quarter ending 2022-12-31 was $0.00.
- Design Therapeutics, Inc. proceeds from sale of productive assets for the quarter ending 2022-09-30 was $0.00.
- Design Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2022 was $39.00K.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $39.00K 10-K · filed 2024-03-19 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $39.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $39.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |